Oncology Medical News about recovery from amenorrhea;premenopausal breast cancer;adjuvant chemotherapy;taxane era

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Determinants of recovery from amenorrhea in premenopausal breast cancer patients receiving adjuvant chemotherapy in the taxane era
Anti-Cancer Drugs, 07/02/09

Minisini AM et al. - In a trial to retrospectively analyze the incidence of amenorrhea after adjuvant chemotherapy and subsequent recovery of menses in 145 breast cancer pts, it was determined that recovery of menses after chemotherapy-induced amenorrhea occurs more probably in younger women, with no pregnancies and receiving taxanes.

Methods

Incidence of amenorrhea after adjuvant chemotherapy and subsequent recovery of menses were analyzed in 145 breast cancer pts.
Age, smoking, alcohol consumption, body mass index, chemotherapy regimen, previous hormonal therapies, and previous childbearing were analyzed as potential predictive factors of ovarian function recovery.

Results

Median age was 42 yrs at the beginning of adjuvant chemotherapy with 30.3% of pts below 40 yrs of age.
The majority (87.6%) of pts received anthracycline-based chemotherapy, 35.2% of pts received a cyclophosphamide-methotrexate-5-fluorouracil regimen, and 42.8% received a taxane.
Incidence of chemotherapy-induced amenorrhea was 80, and 35.3% of these pts resumed menses after a median of 8 mos.
Younger age (<40 yrs) and taxane-based chemotherapy were associated with increased probability of recovery of menses after chemotherapy-induced amenorrhea.
Cyclophosphamide-methotrexate-5-fluorouracil-based chemotherapy and previous childbearing were associated with an increased probability of permanent chemotherapy-induced amenorrhea.

<< Previous
Height and risk of prostate cancer in the prostate, lung,...

Next >>
Prevention of pancreatic cancer by the beta-blocker propranolol